This is a phase I dose-escalation study to evaluate the safety of partially human leukocyte antigen (HLA)-matched multi tumor-associated antigen-specific T cell (TAA-T) therapy for patients with high-risk solid tumors due to the presence of refractory, relapsed and/or minimal residual detectable disease following conventional therapy. Conventional therapy may include chemotherapy, surgery, radiation, autologous stem cell transplant, or targeted therapy.
Diagnosis of high-risk solid tumors known to express at least 2 targeted antigens by either histology or historical reference: Ewing sarcoma, Wilms tumor, neuroblastoma, rhabdomyosarcoma, soft tissue sarcoma, and osteosarcoma.
HLA type and match through at least one allele with antigen-specific activity.
Refractory disease, residual detectable disease following conventional therapy or relapsed disease.
Arm A: age ≥18 years and <70 years
Patients with known human immunodeficiency virus (HIV) infection.
Pregnant or lactating females.
Patients who have undergone previous allogeneic stem cell transplant.
Patients who have undergone previous autologous stem cell transplant within the past 60 days.